A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605). A randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results